On-Topic Virtual Round Table
-
Module 1: Ibrutinib for Hematologic Malignancies_Matthew Davids, MD, MMSc_Catherine Coombs_MD_Anthony Mato, MD, MSCE
9:28
-
Module 1_Introduction and Rationale for Targeting BCMA on MM Cells
10:45
-
Module 2: Acalabrutinib for Hematologic Malignancies_Matthew Davids, MD, MMSc_Catherine Coombs, MD_Anthony Mato, MSCE
8:16
-
Module 2_BCMA-Targeted CAR T-cells
24:20
-
Module 3: Zanubrutinib for Hematologic Malignancies_Matthew Davids, MD, MMSc_Catherine Coombs, Anthony Mato, MD, MSCE
7:59
-
Module 3_BCMA-Targeted Antibody-Drug Conjugates (ADCs)
9:40
-
Module 4: Emerging BTK Inhibitors_Matthew Davids, MD, MMSc_Catherine Coombs, MD_Anthony Mato, MD, MSCE
12:02
-
Module 4_BCMA-Targeted Bispecifics
22:12
-
Module 4_Patient_Caregiver Education
17:09
ASCO #GI22 and #GU22
-
Richard Kim, MD; Moffit Cancer Center; 5Live #GI22
5:33
Key Insights from the ASCO Gastrointestinal Cancers Symposium #GI22
-
Mehmet Akce, MD; Emory University Winship Cancer Institute; 5Live #GI22
5:48
Key Insights from the ASCO Gastrointestinal Cancers Symposium #GI22
-
David Ilson, MD; Memorial Sloan Kettering Cancer Center; 5Live #GI22
5:17
Key Insights from the ASCO Gastrointestinal Cancers Symposium #GI22
-
Aparna Parikh, MD; Harvard Medical School; 5Live #GI22
5:36
Key Insights from the ASCO Gastrointestinal Cancers Symposium #GI22
-
Jacob Berchuck, MD; Dana-Farber Cancer Institute; 5Live #GU22
5:13
Key Insights from the ASCO Genitourinary Cancers Symposium #GU22
